Director
Chartered Patent Attorney
European Patent Attorney
UK Design Attorney
MA Natural Sciences. University of Cambridge
PhD Organic Chemistry, University of Leeds
Thank you
Jonathan is a partner in the Chemical and Life Sciences practice and leads Keltie's Cambridge office. He has extensive experience of working with clients in a wide range of technology areas including agri-tech, sustainability, pharmaceuticals, chemistry, therapeutic treatments, personal care devices, medical devices, medical diagnostics, healthcare, biotechnology, regenerative stem cell therapies, food packaging, gene-editing (CRISPR), CAR-T cell-based therapies, materials, catalysts, energy technologies and cosmetics.
Jonathan manages a number of global patent portfolios for start-ups and SME clients, and his burgeoning practice has a particular focus on start-up and spin-out companies.
Providing his clients with strategic, value-driven advice, Jonathan understands what clients need from their IP portfolio. He has been involved with numerous due diligence exercises for investment rounds, acquisition and licensing, and listings on the UK AIM stock exchange and the Nasdaq in the US.
Jonathan also has an extensive registered design practice and handles the portfolios of European and UK registered designs for a number of household-name international clients.
Prior to joining Keltie in 2011, Jonathan was a principal chemist at GlaxoSmithKline and has almost 10 years’ experience of working in the pharmaceutical sector in the epigenetic, immuno-inflammation, cardiovascular and respiratory disease areas.
Jonathan received a first-class honours degree in Natural Sciences from the University of Cambridge before gaining a PhD in organic chemistry with post-doctoral experience at the distinguished École Polytechnique, Paris, France.
What people think about Jonathan
In recommending Jonathan, the 2020 IAM Patent 1000 noted that he “marries keen biochemistry acumen with industry insight” and stated that he was “a force to be reckoned with”.
The 2022 IAM Patent 1000 further noted that Jonathan is “adept at building IP strategies in line with company development. The Cambridge-based life sciences maven knows his way around pharmaceuticals, biotechnology and growing niches like CRISPR.”
23.02.2021
Patenting ethical, environmental or socially responsible technologiesCan patent protection ever be part of an ethical or high moral value business model?
12.09.2022
The long-term impact of Brexit on trade marks and designsSix years on from the Brexit referendum, we can happily say that the measures put in place for trade marks and designs have been successful in delivering a smooth transition. But IP owners now need to pay attention to upcoming changes to rights of representation, particularly in light of the huge growth in applications at the UK IPO.
OtherLess related knowledge
Thank you
